GILEAD SCIENCES, INC. Long-Term Concentrated

Location: Foster City, CA

CIK: 0000882095 · Show all filings

Period: Q2 2026 (← Previous)

Filing Date: Aug 3, 2026

Total Value: $1.649B (100.0% shares, 0.0% debt)

Holdings (5)

Increased Positions (1)

ASMB Assembly Biosciences Inc. 8.3%

Value $137M (+9.4%) Shares 4,977,089 (+10.5%) Est. Cost $19.87 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
ASMB	Assembly Biosciences Inc.	4,977,089 (+10.5%)	$137M (+9.4%)	8.3%	$19.87	—	COM NEW	045396207

Exited Positions (1)

ACLX Arcellx Inc 46.8%

Value $772M Shares 6,720,803 Est. Cost $86.39 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
ACLX	Arcellx Inc	6,720,803	$772M	46.8%	$86.39	—	—	03940C100

Unchanged Positions (4)

RCUS Arcus Biosciences Inc. 58.8%

Value $969M Shares 31,424,760 Est. Cost $16.13 Unrealized —

KYTX Kyverna Therapeutics Inc. 2.2%

Value $36.76M Shares 4,126,119 Est. Cost $4.79 Unrealized —

GLPG Lakefront Biotherapeutics 30.3%

Value $500M Shares 16,707,477 Est. Cost $27.64 Unrealized —

XLO Xilio Therapeutics Inc. 0.4%

Value $6.231M Shares 650,389 Est. Cost $0.98 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
RCUS	Arcus Biosciences Inc.	31,424,760	$969M	58.8%	$16.13	—	COM	03969F109
KYTX	Kyverna Therapeutics Inc.	4,126,119	$36.76M	2.2%	$4.79	—	COM	501976104
GLPG	Lakefront Biotherapeutics	16,707,477	$500M	30.3%	$27.64	—	SPON ADR	36315X101
XLO	Xilio Therapeutics Inc.	650,389	$6.231M	0.4%	$0.98	—	COM	98422T100